Trial Profile
A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 19 Mar 2019 Status changed from recruiting to completed.
- 07 Jun 2016 Interim results (n=15) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 20 Nov 2015 New trial record